Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Computing
Conference & Expo
November 2-4, 2009 NYC
Register Today and SAVE !..

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
In many cases, the end of the year gives you time to step back and take stock of the last 12 months. This is when many of us take a hard look at what worked and what did not, complete performance reviews, and formulate plans for the coming year. For me, it is all of those things plus a time when I u...
SYS-CON.TV
Novel Cancer Immune Therapy Developer Oncos Therapeutics Ltd. Appoints Experienced Industry Leader Frans Wuite as President and CEO

HELSINKI, November 9, 2012 /PRNewswire/ --

Oncos Therapeutics Ltd., a company developing novel cancer immune therapeutics, announced today that it has appointed Frans Wuite, M.D., M.B.A, as President and Chief Executive Officer and Pekka Simula, M.Sc. (Tech) as Chief Operating Officer.

Frans Wuite brings more than 25 years of leadership experience that spans from start-up to large international companies within the biopharmaceutical industry to Oncos Therapeutics. Prior to joining Oncos, Wuite served in key leadership roles at companies in rapid growth phases. These included Amgen Europe, where he spearheaded the commercial development and launch of Aranesp that soon became Amgen's biggest product.

Pekka Simula, the founding CEO of Oncos since 2008, successfully built Oncos into a clinical stage company. In his role as COO, Simula will be responsible for the company's overall program management covering research, clinical development, process development, and manufacturing.

Prior to Oncos, Simula was Global Program Manager at Varian Medical Systems responsible for the development and market roll-out of the company's entire oncology product suite.  

About Oncos Therapeutics

Oncos Therapeutics develops personalized cancer immunotherapeutics based on its proprietary oncolytic adenovirus technology. The Company has clinical experience on 10 purposefully engineered vaccines. These have a direct oncolytic effect due to selective virus replication in tumor cells, systemic effects through vascular dissemination to metastases, and induction of a strong immune response against tumor cells mediated by exposure of tumor antigens upon oncolysis. In addition, most of Oncos product candidates have a transgene that result in cytokine production in only cancer cells, e.g. GM-CSF, further enhancing the immune response against tumor cells. Oncos' oncolytic vaccine portfolio will be focused on carefully selected cancer types that respond poorly to conventional therapies.

Based on efficacy and safety signals obtained in an Advanced Therapy Access Program (ATAP) with 290 cancer patients, for whom standard of care therapies had failed, CGTG-102 was selected as Oncos' lead product. Clinical experience with 115 CGTG-102-treated patients in ATAP has yielded important information on e.g. optimal dosing and scheduling of the product. CGTG-102 has an orphan indication as its initial target: first line treatment of inoperable Soft Tissue Sarcoma. It is currently in Phase 1 clinical development in Europe and the US. For more information, see http://www.oncos.com.

SOURCE Oncos Therapeutics

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

SOA World Latest Stories
Culture is the most important ingredient of DevOps. The challenge for most organizations is defining and communicating a vision of beneficial DevOps culture for their organizations, and then facilitating the changes needed to achieve that. Often this comes down to an ability to provide...
The essence of cloud computing is that all consumable IT resources are delivered as services. In his session at 15th Cloud Expo, Yung Chou, Technology Evangelist at Microsoft, demonstrated the concepts and implementations of two important cloud computing deliveries: Infrastructure as a...
Without a clear strategy for cost control and an architecture designed with cloud services in mind, costs and operational performance can quickly get out of control. To avoid multiple architectural redesigns requires extensive thought and planning. Boundary (now part of BMC) launched a...
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Mana...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die...
As software becomes more and more complex, we, as software developers, have been splitting up our code into smaller and smaller components. This is also true for the environment in which we run our code: going from bare metal, to VMs to the modern-day Cloud Native world of containers, ...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021


SYS-CON Featured Whitepapers
ADS BY GOOGLE